Ophthalmoplegia Market: Growth Trends, Segmentation, and Key Players (2024-2028)
The Gobal ophthalmoplegia market is projected to grow by USD 435.8 million from 2024 to 2028, at a CAGR of 6%. Ophthalmoplegia is a neurological disorder that affects eye muscle movement, leading to double vision, blurred vision, and muscle weakness. It can be congenital or associated with systemic conditions such as multiple sclerosis and other neurological diseases.Market growth is driven by the increasing prevalence of neurological disorders, the aging population, and the limited treatment options currently available. While advancements in diagnostic tools and medical treatments continue to improve patient care, the market still presents opportunities for innovation in effective and accessible therapies

For more details about the industry, get the PDF sample report for free
Market Segmentation
The ophthalmoplegia market is segmented by end-user, product type, and geography.
By End-User
- Hospitals
- Clinics
- Ambulatory Clinics
By Product Type
- Pharmaceuticals
- Medical Devices
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
Key Market Insights
End-User Insights
The hospitals segment is expected to experience substantial growth as hospitals remain the primary diagnostic and treatment centers for eye movement disorders. Large tertiary care centers and academic medical institutions are equipped with specialized ophthalmology departments and advanced diagnostic tools.
- In 2018, the hospitals segment was valued at USD 723.60 million.
- Hospitals offer multidisciplinary care, including neurologists, ophthalmologists, and rehabilitation services.
- Treatment options include medications, botulinum toxin injections, surgical procedures, and prism glasses.
Market Growth Drivers
1. Growing Geriatric Population
- By 2030, one in six people worldwide will be aged 60 or older.
- The aging population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050.
- The 80+ age group is projected to triple to 426 million by 2050.
- Older individuals are more susceptible to neurological disorders, such as internuclear ophthalmoplegia and inferior rectus muscle dysfunction.
2. Rising Neurological Disorders
- Neurological diseases, including multiple sclerosis, stroke, brain tumors, migraines, and mitochondrial disorders, are increasing.
- According to the WHO (2021), over 3 billion people globally suffer from neurological conditions.
- As these disorders contribute to ophthalmoplegia, demand for medical devices and treatments continues to grow.
Market Challenges
1. Limited Treatment Options
- Current therapies include corticosteroids, immunosuppressants, and surgery, but they are not always effective.
- Patients with rare forms of ophthalmoplegia or those unresponsive to standard treatments have limited options.
- Unmet medical needs drive R&D efforts in gene therapy and stem cell treatments.
Get more details by ordering the complete report
Key Companies in the Ophthalmoplegia Market
Some of the key companies of the Ophthalmoplegia Market are as follows:
- AbbVie Inc.
- Agnitio Pharma
- Atom Pharma
- Care Formulation Labs Pvt Ltd
- Cellera Farma
- Deutsche Pharma Laboratories
- FarmaSyn SA
- GlaxoSmithKline Plc
- Innovative Pharmaceuticals Pvt Ltd
- Medytox
- Merz Pharma GmbH and Co KGaA
- Novartis AG
- Orchidia Pharmaceutical Industries
- Pfizer Inc.
- Sally Pharmacies
- Symbiotec Pharmalab Pvt. Ltd